Refine
Has Fulltext
- yes (64)
Is part of the Bibliography
- yes (64)
Year of publication
Document Type
- Doctoral Thesis (61)
- Journal article (3)
Language
- English (64) (remove)
Keywords
- Maus (64) (remove)
Institute
- Graduate School of Life Sciences (32)
- Theodor-Boveri-Institut für Biowissenschaften (14)
- Rudolf-Virchow-Zentrum (9)
- Neurologische Klinik und Poliklinik (6)
- Institut für Medizinische Strahlenkunde und Zellforschung (4)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (4)
- Institut für Virologie und Immunbiologie (3)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Lehrstuhl für Molekulare Psychiatrie (2)
- Medizinische Fakultät (2)
Sonstige beteiligte Institutionen
The RAF family of protein kinases consists of three members, A-RAF, B-RAF and C-RAF. Unlike the other isotypes, B-RAF has been found to have an important function for normal development of the central nervous system (CNS), because newly generated embryonic neurons lacking B-RAF cannot respond to survival factors and undergo cell death in vitro. A second cell lineage affected by the absence of B-RAF are endothelial cells and their death leads to internal bleedings and lethality of B-RAF-/- mice between embryonic day 10.5 (E10.5) and E12.5 precluding an opportunity to further analyze neural B-RAF function at a later stage. In contrast to B-RAF-/- mice, B-RAFKIN/KIN mice, which are B-RAF deficient but express a chimeric protein consisting of the unique N terminus of B-RAF and all the domains of A-RAF in the B-RAF gene locus, survive after midgestation because their endothelial cells are protected from apoptosis. More importantly, overall prevention of abnormal neural apoptosis in the forebrain allows us to study proliferation- or differentiation-oriented function of B-RAF other than its survival effects in CNS development. The detailed investigation of B-RAFKIN/KIN animals was concentrated on cortical development. There were apparent cortical defects in B-RAFKIN/KIN forebrain: Loss of B-RAF led to severe reduction of Brn-2 expressing pyramidal projection neurons accompanied by a disruption of dendrite formation in the upper layers. In further analysis, BrdU labelling experiments showed that from E14.5 to E16.5 cell proliferation in the ventricular zone of the mutant mice was reduced and that the late-born cortical neurons failed to migrate properly. While the proliferation defect of cortical progenitors was associated with reduced ERK activation, the mechanism causing impaired neuronal migration remains to be determined. Our hypothesis is that the subcellular localization of phospho-ERK may be altered in migrating cortical neurons in B-RAFKIN/KIN mice. To confirm in vivo function of B-RAF and further study unknown roles in embryonic neurogenesis as well as other morphogenesis, conditional B-RAF knockouts would be the ideal models, which can efficiently avoid embryonic lethality, prevent unwanted pleiotropic side effects and exclude accumulative compensatory developmental changes from the earliest developmental stage on, through the deletion of genetic material/gene function in selected cells at a specific time. The use of site-specific recombinases such as Cre and the successful development of the reversible tetracycline-based switch have provided powerful venues for creating conditional loss-of-function mouse models. Generation of tetracycline-regulated B-RAF and floxed B-RAF mouse embryonic stem (ES) cell lines was performed. Up to now, high-grade chimeric mice were obtained after blastocyst injection of the modified ES cell clones. The germline transmission from these chimeric mice is currently under investigation. When either of conditional mouse lines is ready, detailed examination in their CNS development would be done to reveal how B-RAF plays a real role for normal development of the nervous system.
Allergic disease are inflammatory disorders in which aberrant immune regulation occurs, and susceptible individuals mount allergen specific T helper 2 (Th2) responses, which drives disease pathology. Recent studies indicate that Th2 responses that are characteristic of allergic manifestations can be regulated by both naturally occurring CD4+CD25+ regulatory (Treg) cells and antigen-driven IL-10-secreting CD4+ regulatory T cells. Evidence is also emerging that successful Allergen specific immunotherapy (SIT) might work through the induction of IL-10-secreting regulatory T cells. In the first part of this work, I demonstrated the efficiency of allergen specific immunotherapy in the mouse model for allergic airway inflammation. Here I could show that intranasal administration of SIT abrogates allergic symptoms more efficiently, than the subcutaneous treatment. Furthermore, an IL-4/IL-13 (QY) inhibitor was used as an adjuvant for SIT, which has been demonstrated to have an anti-allergic potential, when administered prophylactically during allergic sensitization. However, the combination therapy with SIT and the inhibitory molecule QY did not show any significant enhancement in regards to all measured allergic parameters, when compared to monotherapy with SIT. These results provide the evidence, that shift from Th2 to Th1 cytokine profile might not be a key event in successful SIT. Subsequently, the investigation of immune mechanisms under successful SIT demonstrate that the increase of IL-10 secreting CD4+ T regulatory cells is associated with the suppression of airway inflammation in our mouse system, suggesting that these T cell subsets might be involved in the regulatory mechanisms of allergic disorders. In agreement with these findings is the second part of this work, where superagonistic a-CD28 mAb´s were used for the expansion of T regulatory cell subsets in our murine model for allergic airway inflammation. Here I could show, that the application of a-CD28 mAb during allergic sensitization, resulted in the establishment of a Th2 state, rather than a stimulation of a Treg cell population, supporting the Th2 promoting role of a-CD28 mAb together with TCR engagement. However, interesting findings were obtained by application of the superagonistic a-CD28 mAb in the challenge phase in established allergy. Conversely to the previous experiment, therapeutic administration of a-CD28 mAb lead to the generation of IL-10 secreting CD4+CD25+ T cell population in line with the induction of anti-allergic effects. Taking together the results of this study argue for the anti-inflammatory properties of T regulatory cells in allergic disease and highlights importance of these T cell subsets in the suppression of Th2 cell-driven response to allergen. Moreover, these observations suggest that the induction of IL-10 in vivo by T regulatory cells may represent a novel treatment strategy for allergic disorders.
Human cytomegalovirus (HCMV) infection causes clinical symptoms in immunocompromised individuals such as transplantant recipients and AIDS patients. The virus is also responsible for severe complications in unborn children and young infants. The species specificity of HCMV prevents the direct study of mechanisms controlling the infection in animal models. Instead, the murine cytomegalovirus (MCMV) is used as a model system. Human and murine CMVs have large double-stranded DNA genomes, encoding nearly 170 genes. About 30% of the genes are committed to essential tasks of the virus. The remaining genes are involved in virus pathogenesis or host interaction and are dispensable for virus replication. The CMV genes are classified in gene families, based on sequence homology. In the present work, the function of two genes of the US22 gene family was analyzed. The MCMV genes m142 and m143 are the only members of this family that are essential for virus replication. These genes also differ from the remaining ten US22 gene family members in that they lack 1 of 4 conserved sequence motifs that are characteristic of this family. The same conserved motif is missing in the HCMV US22 family members TRS1 and IRS1, suggesting a possible functional homology. To demonstrate an essential role of m142 and m143, the genes were deleted from the MCMV genome, and the mutants were reconstituted on complementing cells. Infection of non-complementing cells with the deletion mutants did not result in virus replication. Virus growth was rescued by reinsertion of the corresponding genes. Cells infected with the viral deletion mutants synthesized reduced amounts of viral DNA, and viral late genes were not expressed. However, RNA analyses showed that late transcripts were present, excluding a role of m142 and m143 in regulation of gene transcription. Metabolic labelling experiments showed that total protein synthesis at late times postinfection was impaired in cells infected with deletion mutants. Moreover, the dsRNA-dependent protein kinase R (PKR) and its target protein, the translation initiation factor 2α (eIF2α) were phosphorylated in these cells. This suggested that the m142 and m143 are required for blocking the PKR-mediated shut-down of protein synthesis. Expression of the HCMV gene TRS1, a known inhibitor of PKR activation, rescued the replication of the deletion mutants, supporting the observation that m142 and m143 are required to inhibit this innate immune response of the host cell.
The aim of the present study was to design different dosage forms as carrier systems to deliver sorafenib to the lung of BXB-23 transgenic mice using different routes of administration. Three dosage forms were used one of them was an oil-in-water emulsion and the oral route was chosen for this experiment. The other delivery system was a liposome preparation for intratracheal instillation. In this case the oral route was considered as a control experiment. The last dosage form was PLGA microspheres. Before sorafenib administration it was important to develop a HPLC method to assess sorafenib absorption after its administration and to determine its concentrations in mouse serum. The HPLC method allowed sorafenib quantification in small volumes (30 µl) of mouse serum and tissues. The developed HPLC method was validated resulting in satisfactory selectivity, good linearity, good accuracy and precision over the concentration range examined. Sorafenib was successfully incorporated in a fat emulsion (o/w) using a traditional method resulting in a white homogenous emulsion and no particle aggregation was observed. Sorafenib exhibited antitumor activity on the lung adenoma in BXB-23 transgenic mice when administered orally (2 mg sorafenib per mouse) in the emulsion preparation. The determined effect was an approximately 29 % reduction in the tumor area of the adenoma foci and a proliferation reduction. In order to improve the pharmacological effects of sorafenib on the lung adenoma in BXB-23 mice, the targeting of sorafenib directly to the site of action (the lung) was an attractive concept. For this purpose the intratracheal route was used. Since sorafenib administration by instillation required incorporation of sorafenib in a dosage form suitable for its lipophilic nature, a liposome suspension was the second dosage form used. A lyophilization method was employed for sorafenib liposome preparation utilizing dilauroylphosphatidylcholine (DLPC) which is safe and tolerable for the lung. Incorporation of sorafenib in the liposomes did not influence the particle size and its distribution. The sorafenib liposomes showed high encapsulation efficiency, good stability at 4 °C for one month and satisfactory in vitro release properties and inhibited Raf-1 mediated activation of ERK in cell culture assay. In a pharmacokinetic experiment sorafenib loaded liposomes were instilled directly into the lung. The results revealed that a significant level of sorafenib was achieved in the lung tissues after 2 hours and then reduced after 48 h and remained nearly constant for one week. On the other hand, only traces of sorafenib were found in the mice serum up to 48 h. Subsequently, the pharmacological activity of sorafenib (1 mg per mouse) was studied when delivered in a liposomal suspension intratracheally to treat the lung adenoma of BXB-23 mice. The data of this experiment demonstrated that sorafenib intratracheal instillation resulted in a reduction of tumor area of adenoma foci (67 %) and an elevation of the percent of apoptotic cells. In contrast, prolongation of the treatment period did not further enhance sorafenib activity on the lung adenoma. This previous finding suggested a development of multidrug resistance (MDR) by the adenoma foci cells against sorafenib instillation, which was examined by immunohistochemistry staining. The percent of MDR positive cells was higher after two and three weeks sorafenib liposome instillation treatment than that after one week treatment. The last dosage form used for sorafenib was microspheres, which were prepared by emulsion-diffusion-evaporation method using biodegradable PLGA 50:50 resulting in a white lyophilized powder. The system was characterized physicochemically and revealed a good microspheres yield, high encapsulation efficiency, a homogenous particle size distribution and slow in vitro release of sorafenib. The other strategy studied in the present research project was gene delivery to target the lung bearing tumor of BXB-23 mice using a non-viral vector (polyethylenimine). Polyethylenimine (PEI) was used to investigate its efficiency in transfecting lung bearing tumor of BXB-23 mice model and its ability to transfect the adenoma foci cells. LacZ, which encodes Beta-galactosidase was used in the present study as a reporter gene and was complexed with PEI before delivered intravenously. A high LacZ expression in the alveolar region with some expression in the adenoma foci was observed. On contrary, a low LacZ expression in the alveoli and in the adenoma foci was achieved after instillation of the same polyplex intratracheally.
Several lines of evidence implicate a dysregulation of tryptophan hydroxylase (TPH)-dependent serotonin (5-HT) synthesis in emotions and stress and point to their potential relevance to the etiology and pathogenesis of various neuropsychiatric disorders. However, the differential expression pattern of the two isoforms TPH1 and TPH2 which encode two forms of the rate-limiting enzyme of 5-HT synthesis is controversial. Here, a comprehensive spatio-temporal analysis clarifies TPH1 and TPH2 expression during pre- and postnatal development of the mouse brain and in adult human brain as well as in peripheral organs including the pineal gland. Four different methods (real time PCR, in situ hybridization, immunohistochemistry and Western blot analysis) were performed to systematically control for tissue-, species- and isoform-specific expression on both the pre- and posttranslational level. TPH2 expression was consistently detected in the raphe nuclei, as well as in fibres in the deep pineal gland and in the gastrointestinal tract. Although TPH1 expression was found in these peripheral tissues, no significant TPH1 expression was detected in the brain, neither during murine development, nor in mouse and human adult brain. Also under conditions like stress and clearing the tissue from blood cells, no changes in expression levels were detectable. Furthermore, the reuptake of 5-HT into the presynaptic neuron by the serotonin transporter (SERT) is the major mechanism terminating the neurotransmitter signal. Thus, mice with a deletion in the Sert gene (Sert KO mice) provide an adequate model for human affective disorders to study lifelong modified 5-HT homeostasis in interaction with stressful life events. To further explore the role of TPH isoforms, Tph1 and Tph2 expression was studied in the raphe nuclei of Sert deficient mice under normal conditions as well as following exposure to acute immobilization stress. Interestingly, no statistically significant changes in expression were detected. Moreover, in comparison to Tph2, no relevant Tph1 expression was detected in the brain independent from genotype, gender and treatment confirming expression in data from native animals. Raphe neurons of a brain-specific Tph2 conditional knockout (cKO) model were completely devoid of Tph2-positive neurons and consequently 5-HT in the brain, with no compensatory activation of Tph1 expression. In addition, a time-specific Tph2 inducible (i) KO mouse provides a brain-specific knockdown model during adult life, resulting in a highly reduced number of Tph2-positive cells and 5-HT in the brain. Intriguingly, expression studies detected no obvious alteration in expression of 5-HT system-associated genes in these brain-specific Tph2 knockout and knockdown models. The findings on the one hand confirm the specificity of Tph2 in brain 5-HT synthesis across the lifespan and on the other hand indicate that neither developmental nor adult Tph2-dependent 5-HT synthesis is required for normal formation of the serotonergic system, although Tph1 does not compensate for the lack of 5-HT in the brain of Tph2 KO models. A further aim of this thesis was to investigate the expression of the neuropeptide oxytocin, which is primarily produced in the hypothalamus and released for instance in response to stimulation of 5-HT and selective serotonin reuptake inhibitors (SSRIs). Oxytocin acts as a neuromodulator within the central nervous system (CNS) and is critically involved in mediating pain modulation, anxiolytic-like effects and decrease of stress response, thereby reducing the risk for emotional disorders. In this study, the expression levels of oxytocin in different brain regions of interest (cortex, hippocampus, amygdala, hypothalamus and raphe nuclei) from female and male wildtype (WT) and Sert KO mice with or without exposure to acute immobilization stress were investigated. Results showed significantly higher expression levels of oxytocin in brain regions which are involved in the regulation of emotional stimuli (amygdala and hippocampus) of stressed male WT mice, whereas male Sert KO as well as female WT and Sert KO mice lack these stress-induced changes. These findings are in accordance with the hypothesis of oxytocin being necessary for protection against stress, depressive mood and anxiety but suggest gender-dependent differences. The lack of altered oxytocin expression in Sert KO mice also indicates a modulation of the oxytocin response by the serotonergic system and provides novel research perspectives with respect to altered response of Sert KO mice to stress and anxiety inducing stimuli.
Prion diseases such as scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle or Creutzfeldt-Jakob disease (CJD) in humans are fatal neurodegenerative disorders characterized by brain lesions and the accumulation of a disease-associated protein, designated PrPSc. How prions proceed to damage neurons and whether all or only subsets of neurons have to be affected for the onset of the clinical disease is still elusive. The manifestation of clinical prion disease is characterized by motor dysfunctions, dementia and death. Furthermore loss of motor neurons (MN) in the spinal cord is a constant finding in different mouse models of prion disease, suggesting that MN are vulnerable cells for triggering the onset of clinical symptoms. To determine whether the protection of MN against prion induced dysfunctions is an approach for holding the disease at the sub-clinical level, we established a novel conditional model for Cre-mediated expression of a dominant-negative PrP mutant (PrPQ167R) in the cells of interest. Dominant-negative PrP mutants provide protection of prion induced dysfunctions by inhibiting prion replication. Transgenic mice were generated carrying a floxed LacZ marker gene followed by the coding sequence of PrPQ167R under control of the human ubiquitin C promoter. Two Cre strains have been used to direct PrPQ167R expression either to a subset of MN of the spinal cord (Hb9-Cre) or to various neuronal cell populations of the spinal cord and brain (NF-L-Cre). Transgenic mice were infected with mouse-adapted prions via different inoculation routes (intranerval, intracerebral and intraperitoneal) and monitored for effects on incubation time and pathology. Tg floxed LacZ-PrPQ167R/NF-L-Cre mice showed about 15% prolonged survival upon intraperitoneal low dose prion infection, whereas survival of Tg floxed LacZ-PrPQ167R/Hb9-Cre mice was comparable to control littermates. The results suggest that the protection of spinal MN prolongs the incubation period but is not sufficient to completely inhibit clinical prion disease. In a second approach, Cre was transferred into the hind limb muscles of transgenic mice via a double-stranded adeno-associated virus vector (dsAAV2-Cre). The goal of this strategy was to target a broader cell population and thus to enhance expression levels of protective PrPQ167R in the spinal cord of Tg floxed-LacZ-PrPQ167R mice. After intramuscular (i.m.) application of dsAAV2-Cre, exhibiting a physical titer of 5x1010 GP/ml, recombinant transgenic DNA was detected only in the muscle tissue, pointing out that functional Cre-recombinase was expressed at the side of virus application. However, dsAAV2-Cre did neither induce recombination of transgenic DNA in the spinal cord or brain nor expression of dominant-negative PrPQ167R. In conclusion the dsAAV2-Cre vectors system needs further improvement to achieve efficient transport from muscle tissue to the central nervous system (CNS). 105 7 SUMMARY The lymphoreticular system (LRS) is an early site of prion replication. In splenic tissue prion infectivity is associated with follicular dendritic cells (FDC) as well as with Band T-lymphocytes. However, it is still unknown if those cell types are able to replicate the infectious agent or if other PrP-expressing cell types are engaged. To investigate if neurons and in particular MN are involved, transgenic mice carrying one allele of floxed Prnp (lox2+=��) and either one allele of Hb9-Cre or NF-L-Cre were generated on a Prnp0=0 background. Therefore a conditional PrP knockout was established in a subset of MN of the spinal cord (Hb9-Cre) or in various neuronal populations of the spinal cord and brain (NF-L-Cre). Transgenic mice were inoculated with prions to study the accumulation of PrPSc and prion infectivity in spleen and spinal cord at an early time point after infection. The findings show that PrPSc accumulation in mice with MN-specific PrP depletion (lox2+=��/ Hb9-Cre) was comparable to control littermates, while pan-neuronal PrP deficient mice (lox2+=��/NF-L-Cre) were not able to accumulate PrPSc in splenic tissue until 50 days post inoculation. Moreover spleens of lox2+=��/NF-L-Cre mice exhibited a clearly reduced prion infectivity titer, suggesting that accumulation of prions in the spleen is dependent on PrP expression in the nervous tissue.
Background: Anticoagulation is an important means to prevent from acute ischemic stroke but is associated with a significant risk of severe hemorrhages. Previous studies have shown that blood coagulation factor XII (FXII)- deficient mice are protected from pathological thrombus formation during cerebral ischemia without bearing an increased bleeding tendency. Hence, pharmacological blockade of FXII might be a promising and safe approach to prevent acute ischemic stroke and possibly other thromboembolic disorders but pharmacological inhibitors selective over FXII are still lacking. In the present study we investigated the efficacy of COU254, a novel nonpeptidic 3-carboxamide-coumarin that selectively blocks FXII activity, on stroke development and post stroke functional outcome in mice. Methods: C57Bl/6 mice were treated with COU254 (40 mg/kg i.p.) or vehicle and subjected to 60 min transient middle cerebral artery occlusion (tMCAO) using the intraluminal filament method. After 24 h infarct volumes were determined from 2,3,5-Triphenyltetrazoliumchloride(TTC)-stained brain sections and functional scores were assessed. Hematoxylin and eosin (H&E) staining was used to estimate the extent of neuronal cell damage. Thrombus formation within the infarcted brain areas was analyzed by immunoblot. Results: Infarct volumes and functional outcomes on day 1 after tMCAO did not significantly differ between COU254 pre-treated mice or untreated controls (p > 0.05). Histology revealed extensive ischemic neuronal damage regularly including the cortex and the basal ganglia in both groups. COU254 treatment did not prevent intracerebral fibrin(ogen) formation. Conclusions: COU254 at the given concentration of 40 mg/kg failed to demonstrate efficacy in acute ischemic stroke in this preliminary study. Further preclinical evaluation of 3-carboxamide-coumarins is needed before the antithrombotic potential of this novel class of FXII inhibitors can be finally judged.
Background Transgenic mouse models are increasingly used to study the pathophysiology of human cardiovascular diseases. The aortic pulse wave velocity (PWV) is an indirect measure for vascular stiffness and a marker for cardiovascular risk. Results This work presents three MR-methods that allow the determination of the PWV in the descending murine aorta by analyzing blood flow waveforms, arterial distension waveforms, and a method that uses the combination of flow and distension waveforms. Systolic flow pulses were recorded with a temporal resolution of 1 ms applying phase velocity encoding. In a first step, the MR methods were validated by pressure waveform measurements on pulsatile elastic vessel phantoms. In a second step, the MR methods were applied to measure PWVs in a group of five eight-month-old apolipoprotein E deficient (ApoE(-/-)) mice and an age matched group of four C57Bl/6J mice. The ApoE(-/-) group had a higher mean PWV than the C57Bl/6J group. Depending on the measurement technique, the differences were or were not statistically significant. Conclusions The findings of this study demonstrate that high field MRI is applicable to non-invasively determine and distinguish PWVs in the arterial system of healthy and diseased groups of mice.
Growth factor induced signaling cascades are key regulatory elements in tissue development, maintenance and regeneration. Deregulation of the cascades has severe consequences, leading to developmental disorders and neoplastic diseases. As a major function in signal transduction, activating mutations in RAF family kinases are the cause of many human cancers. In the first project described in this thesis we focused on B-RAF V600E that has been identified as the most prevalent B-RAF mutant in human cancer. In order to address the oncogenic function of B-RAF V600E, we have generated transgenic mice expressing the activated oncogene specifically in lung alveolar epithelial type II cells. Constitutive expression of B-RAF V600E caused abnormalities in alveolar epithelium formation that led to airspace enlargements. These lung lesions showed signs of tissue remodeling and were often associated with chronic inflammation and low incidence of lung tumors. Inflammatory cell infiltration did not precede the formation of emphysema-like lesions but was rather accompanied with late tumor development. These data support a model where the continuous regenerative process initiated by oncogenic B-RAF-driven alveolar disruption provides a tumor-promoting environment associated with chronic inflammation. In the second project we focused on wild type B-RAF and its role in an oncogenic-C-RAF driven mouse lung tumor model. Toward this aim we have generated compound mice in which we could conditionally deplete B-RAF in oncogenic-C-RAF driven lung tumors. Conditional elimination of B-RAF did not block lung tumor formation however led to reduced tumor growth. The diminished tumor growth was not caused by increased cell death instead was a consequence of reduced cell proliferation. Moreover, B-RAF ablation caused a reduction in the amplitude of the mitogenic signalling cascade. These data indicate that in vivo B-RAF is dispensable for the oncogenic potential of active C-RAF; however it cooperates with oncogenic C-RAF in the activation of the mitogenic cascade.
Background: We evaluated the effect of insulin stimulation and dietary changes on myocardial, skeletal muscle and brain [18F]-fluorodeoxyglucose (FDG) kinetics and uptake in vivo in intact mice. Methods: Mice were anesthetized with isoflurane and imaged under different conditions: non-fasted (n = 7; "controls"), non-fasted with insulin (2 IU/kg body weight) injected subcutaneously immediately prior to FDG (n = 6), fasted (n = 5), and fasted with insulin injection (n = 5). A 60-min small-animal PET with serial blood sampling and kinetic modeling was performed. Results: We found comparable FDG standardized uptake values (SUVs) in myocardium in the non-fasted controls and non-fasted-insulin injected group (SUV 45-60 min, 9.58 ± 1.62 vs. 9.98 ± 2.44; p = 0.74), a lower myocardial SUV was noted in the fasted group (3.48 ± 1.73; p < 0.001). In contrast, the FDG uptake rate constant (Ki) for myocardium increased significantly by 47% in non-fasted mice by insulin (13.4 ± 3.9 ml/min/100 g vs. 19.8 ± 3.3 ml/min/100 g; p = 0.030); in fasted mice, a lower myocardial Ki as compared to controls was observed (3.3 ± 1.9 ml/min/100 g; p < 0.001). Skeletal muscle SUVs and Ki values were increased by insulin independent of dietary state, whereas in the brain, those parameters were not influenced by fasting or administration of insulin. Fasting led to a reduction in glucose metabolic rate in the myocardium (19.41 ± 5.39 vs. 3.26 ± 1.97 mg/min/100 g; p < 0.001), the skeletal muscle (1.06 ± 0.34 vs. 0.34 ± 0.08 mg/min/100 g; p = 0.001) but not the brain (3.21 ± 0.53 vs. 2.85 ± 0.25 mg/min/100 g; p = 0.19). Conclusions: Changes in organ SUVs, uptake rate constants and metabolic rates induced by fasting and insulin administration as observed in intact mice by small-animal PET imaging are consistent with those observed in isolated heart/muscle preparations and, more importantly, in vivo studies in larger animals and in humans. When assessing the effect of insulin on the myocardial glucose metabolism of non-fasted mice, it is not sufficient to just calculate the SUV - dynamic imaging with kinetic modeling is necessary.